Modified Linggui Zhugan Decoction () Ameliorates Glycolipid Metabolism and Inflammation via PI3K-Akt/mTOR-S6K1/AMPK-PGC-1 α Signaling Pathways in Obese Type 2 Diabetic Rats

Chinese Journal of Integrative Medicine
Jia-Pan SunBin Ke

Abstract

To investigate the protective effects of modified Linggui Zhugan Decoction (, MLZD), a traditional Chinese medicine formula, on obese type 2 diabetes mellitus (T2DM) rats. Fifty Sprague-Dawley rats were randomly divided into 5 groups by a random number table, including normal, obese T2DM (ob-T2DM), MLZD low-dose [MLDZ-L, 4.625 g/(kg·d)], MLZD middle-dose [MLD-M, 9.25 g/(kg·d) ] and MLZD high-dose [MLD-H, 18.5 g/(kg·d)] groups, 10 rats in each group. After 4-week intervention, blood samples and liver, pancreas, muscle tissues were collected to assess the insulin resistance (IR), blood lipid, adipokines and inflammation cytokines. The alteration of phosphatidylinositol 3 kinase (PI3K)-protein kinase B (PKB or Akt)/the mammalian target of rapamycin (mTOR)-ribosome protein subunit 6 kinase 1 (S6K1 )/AMP-activated protein kinase (AMPK)-peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 α) pathways were also studied. MLZD dose-dependently reduced fasting blood glucose, fasting insulin, homeostasis model of assessment for IR index and increased insulin sensitive index compared with ob-T2DM rats (P<0.05). Similarly, total cholesterol, triglyceride, low-density lipoprotein cholesterol and free fatty acids were a...Continue Reading

References

Jul 24, 2001·JAMA : the Journal of the American Medical Association·A D PradhanP M Ridker
Jan 18, 2002·Nature·Yasuhiko MinokoshiBarbara B Kahn
Apr 25, 2007·Trends in Molecular Medicine·Stephen G DannGeorge Thomas
May 25, 2010·Current Protein & Peptide Science·Hongyu Zhou, Shile Huang
Jul 9, 2010·Lancet·Varman T SamuelGerald I Shulman
Mar 23, 2012·Nature Reviews. Molecular Cell Biology·D Grahame HardieSimon A Hawley
Sep 7, 2012·Cold Spring Harbor Perspectives in Biology·Brian A Hemmings, David F Restuccia
Apr 3, 2014·American Journal of Physiology. Endocrinology and Metabolism·Victoria L B NelsonRichard Z Lin
Apr 5, 2014·British Journal of Pharmacology·Dan QuYu Huang
Jul 22, 2014·Metabolism: Clinical and Experimental·Zhixia SongXiaoliang Zhang
Aug 12, 2014·Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan·Yubin YangJian Qin
Nov 12, 2015·World Journal of Diabetes·Chandra Kanti Chakraborti
Dec 15, 2015·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Bart VanhaesebroeckRoberto Piñeiro
Apr 9, 2016·Journal of Basic and Clinical Pharmacy·Anroop B Nair, Shery Jacob
Apr 21, 2016·The Journal of Endocrinology·Haijiang WuHuijun Duan
Jun 13, 2017·The New England Journal of Medicine·UNKNOWN GBD 2015 Obesity CollaboratorsChristopher J L Murray
Aug 5, 2017·Journal of Cellular Physiology·Rosa Castilla-MadrigalMaría Pilar Lostao
Mar 9, 2018·Endocrine Reviews·George A BrayThomas H Inge
Sep 29, 2018·International Journal of Biological Sciences·Xingjun HuangZhengquan Su
Nov 23, 2018·Diabetologia·Philipp E Scherer
Jun 4, 2019·Cytokine·Abhijit A Ghadge, Amrita A Khaire
Aug 2, 2019·World Journal of Gastroenterology : WJG·Meng-Ting LiuJian Qin
Dec 6, 2019·Nature·Michael Roden, Gerald I Shulman

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.